8 recruiting, 6 not yet recruiting, 2 completed, 1 unknown. 8 Phase 1, 6 Phase 2, 4 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Not yet recruiting 4, Recruiting 4 |
| Phase 2 | 6 | Recruiting 3, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 4 | Completed 2, Not yet recruiting 2 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow HS-20093: new trials by email Literature Review of HS-20093 trials Research Report on HS-20093
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer HS-20093, Ivonescimab, Chemotherapy - Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 102 | 2026-11-10 | 2026-10-27 |
| A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer HRS-2329 Tablet, Nimotuzumab, HS-20093 - Pancreatic Cancer, RAS Mutations or Amplifications | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang University | 80 | 2026-08-15 | 2026-08-31 |
| A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations HS-20093, Docetaxel - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Hansoh BioMedical R&D Company | 450 | 2026-03-31 | 2026-03-11 |
| A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases Risvutatug rezetecan - Glioblastoma (GBM), Brain Metastasases | Early Phase 1 | Recruiting | Nader Sanai | 15 | 2026-02-11 | 2026-03-06 |
| Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors HS-20093, Itraconazole - Advanced Solid Tumors | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 18 | 2025-09-23 | 2026-01-16 |
| Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer HS-20093, HRS-5041 - Advanced Prostate Cancer | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 63 | 2025-08-19 | 2025-12-05 |
| A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors HS-10370, HS-20117, Adebrelimab - Advanced Solid Tumors, Colorectal Cancer | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 762 | 2025-05-30 | 2025-05-09 |
| Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure HS-20093, Gemcitabine combined with docetaxel - Osteosarcoma | Phase 3 | Completed | Hansoh BioMedical R&D Company | 122 | 2025-04-25 | 2026-10-19 |
| ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. HS-20093, Anlotinib, Epirubicin - Osteosarcoma, Soft Tissue Sarcoma (STS) | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 448 | 2024-12-20 | 2024-11-21 |
| ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer HS-20093 - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Withdrawn | Hansoh BioMedical R&D Company | 2024-11-30 | 2024-03-04 | |
| ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer HS-20093, Bevacizumab, 5-FU - Metastatic Colorectal Cancer (CRC) | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 560 | 2024-10-03 | 2025-02-13 |
| A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer HS-20093 - Limited-stage Small-cell Lung Cancer | Phase 3 | Not yet recruiting | Hansoh BioMedical R&D Company | 406 | 2024-09-30 | 2024-07-30 |
| ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer HS-20093, Topotecan - Small Cell Lung Cancer | Phase 3 | Completed | Hansoh BioMedical R&D Company | 461 | 2024-07-04 | 2026-10-16 |
| ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors HS-20093, Adebrelimab, Cisplatin/ Carboplatin - Advanced Solid Tumor | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 610 | 2024-04-26 | 2024-07-18 |
| HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors HS-20093 - Advanced Solid Tumor | Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 220 | 2024-02-06 | 2024-12-02 |
| ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors HS-20093 - Metastasis Castration Resistant Prostate Cancer(mCRPC) | Phase 2 | Unknown | Hansoh BioMedical R&D Company | 120 | 2024-01-18 | 2024-08-20 |
| ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors HS-20093 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 170 | 2023-12-18 | 2024-08-20 |
| ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas HS-20093 - Osteosarcoma, Sarcoma | Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 170 | 2023-06-08 | 2024-08-23 |
Carcinoma, Non-Small-Cell Lung (3) · Osteosarcoma (3) · Colorectal Neoplasms (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Esophageal Neoplasms (1) · Glioblastoma (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Hansoh BioMedical R&D Company (15) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Nader Sanai (1) · Zhejiang University (1)
China (12) · United States (1)
Nader Sanai, MD (1) · Wei Guo, MD (1)